Latest Health News

Helloworld Travel Limited reported a mixed FY25 performance with an 8.6% decline in Total Transaction Value but a rise in underlying EBITDA, alongside a fully franked final dividend and a strategic acquisition in New Zealand.

Bio-Gene Technology Limited reported a net loss of AUD 2.58 million for FY2025 while making significant strides in developing its bio-insecticides Flavocide and Qcide, securing US Department of Defense grants and expanding global partnerships.

SPC Global Holdings is transitioning its senior financing from Scottish Pacific to Commonwealth Bank, locking in $154 million in total facilities and expected to save $3 million annually in interest. This move positions the company for accelerated growth both in Australia and abroad.

Sandon Capital Investments has announced a modest increase in its annual dividend and will begin paying fully franked dividends monthly, aiming to provide shareholders with more frequent income amid a changing economic backdrop.

Johns Lyng Group reported a modest revenue increase to $1.18 billion in FY25, driven by organic growth and key acquisitions, while agreeing to a $1.1 billion takeover scheme with Pacific Equity Partners.

Centrepoint Alliance reported a 13.5% revenue increase and a 30.6% rise in pre-tax profit for the year ended June 2025, yet net profit after tax fell by 33.7%. The company maintained its final dividend at 1.75 cents per share.

Aurelia Metals Limited has reported a strong turnaround with a $48.9 million net profit for FY25, driven by operational progress at its Federation Mine and the approval of the Great Cobar Project. The company’s strategic focus on base metals growth and sustainability underpins its improved financial and safety performance.

Mader Group Limited has reported a solid 13% increase in both revenue and profit for the 2025 financial year, accompanied by a notable rise in dividends.

Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Noumi Limited reported a 13% rise in adjusted operating EBITDA for FY25, driven by strong growth in its plant-based milks and dairy segments. The company has resolved legacy litigation issues and is now focused on navigating the $610 million convertible note maturity due in 2027.

Noumi Limited has posted a significant $150 million loss for the year ending June 2025, driven by non-cash charges and raising questions about its financial stability.